The State of Cytokines: Momentum, Maturation, and Strategic Shift
Drawing on Beacon data, the 2025 Landscape Review delivers a clear, structured view of how the cytokine space evolved in 2025 and where competitive pressure and opportunity are building next.
Inside the report, we highlight:
- A pipeline increasingly weighted toward mid- and late-stage progression
- Sustained strength in validated pathways like TNF and IL-2, alongside rising momentum in IL-23
- Engineering strategies such as pegylation and Fc-fusion dominating late-stage programs
- Cytokine-related clinical trials increased to 918 in 2025, up from 878 in 2024 and nearing 2021-2022 peak levels
- A deal landscape defined by fewer but higher-value strategic transactions
- Regulatory activity led by IND/CTA approvals, signalling sustained early-stage pipeline entry
The Drug Landscape
An in-depth analysis of the global cytokine pipeline, covering therapeutic class distribution, target momentum, cytokine engineering strategies, and disease focus across immunology and oncology.
The Trial Landscape
A detailed look at cytokine clinical activity in 2025, including year-on-year trial growth, phase distribution across cytokine classes, disease breakdown, trial completions, and reasons for terminations.
The Commercial Landscape
An overview of cytokine deal activity and company dynamics, exploring deal value vs. volume trends, the shift toward strategic licensing and M&A, deal types in 2025, company type distribution, and global headquarters concentration.
The Future of the Cytokine Landscape
A forward-looking view of assets to watch and key 2026 milestones, including late-stage trial readouts, regulatory decisions, and programs positioned to shape the next phase of cytokine development.
Regulatory Announcements
A snapshot of 2025 regulatory milestones, highlighting the dominance of IND/CTA approvals, drug approvals, breakthrough designations, and the assets generating the highest levels of regulatory activity.
Previous Cytokine Landscape Reviews
H1 2025 Landscape Review
2024 Landscape Review
H1 2024 Landscape Review
You May Also Be Interested In…
Learn More About Cytokine
- The Most Comprehensive Way to Search the Cytokine Drug Development Landscape: Unique search ontologies based on Cytokine drug and trial characteristics
- Market Leading Approach to Cytokine Preclinical & Clinical Data Curation: Manual curation of key Cytokine research and development data points by Cytokine research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cytokine company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
